Gelbard MK - Search Results

1

Clinical Significance of Shortened Penile Length and Alterations in Penile Length Following Treatment for Peyronie's Disease.

Goldstein I, Gelbard MK, Lipshultz LI. Goldstein I, et al. Among authors: gelbard mk. Sex Med Rev. 2022 Jul;10(3):409-420. doi: 10.1016/j.sxmr.2021.12.005. Sex Med Rev. 2022. PMID: 35772849 Review.

2

Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.

Gelbard M, Hellstrom WJ, McMahon CG, Levine LA, Smith T, Tursi J, Kaufman G, Goldstein I. Gelbard M, et al. J Sex Med. 2013 Nov;10(11):2822-31. doi: 10.1111/jsm.12312. Epub 2013 Sep 24. J Sex Med. 2013. PMID: 24112401 Clinical Trial.

3

Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease.

Goldstein I, Lipshultz LI, McLane M, Hu Y, Xiang Q, Liu G, Vijayan S, Gelbard MK. Goldstein I, et al. Among authors: gelbard mk. J Urol. 2020 Jun;203(6):1191-1197. doi: 10.1097/JU.0000000000000743. Epub 2020 Jan 10. J Urol. 2020. PMID: 31922462 Clinical Trial.

4

Long-term Curvature Deformity Characterization in Men Previously Treated With Collagenase Clostridium Histolyticum for Peyronie's Disease, Subgrouped by Penile Plaque Calcification.

Goldstein I, McLane MP, Xiang Q, Wolfe HR, Hu Y, Gelbard MK. Goldstein I, et al. Among authors: gelbard mk. Urology. 2020 Dec;146:145-151. doi: 10.1016/j.urology.2020.08.045. Epub 2020 Sep 4. Urology. 2020. PMID: 32896582

5

Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease.

Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Gelbard M, et al. J Urol. 2012 Jun;187(6):2268-74. doi: 10.1016/j.juro.2012.01.032. Epub 2012 Apr 13. J Urol. 2012. PMID: 22503048 Clinical Trial.

6

Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.

Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd. Gelbard M, et al. J Urol. 2013 Jul;190(1):199-207. doi: 10.1016/j.juro.2013.01.087. Epub 2013 Jan 31. J Urol. 2013. PMID: 23376148 Review.

7

Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach.

Gelbard MK, Chagan L, Tursi JP. Gelbard MK, et al. J Sex Med. 2015 Jun;12(6):1481-9. doi: 10.1111/jsm.12904. Epub 2015 May 5. J Sex Med. 2015. PMID: 25940867 Review.

8

Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.

Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, Kaufman GJ, Tursi JP, Ralph DJ. Levine LA, et al. Among authors: gelbard mk. J Sex Med. 2015 Jan;12(1):248-58. doi: 10.1111/jsm.12731. Epub 2014 Nov 12. J Sex Med. 2015. PMID: 25388099 Clinical Trial.

9

Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study.

Gelbard MK, James K, Riach P, Dorey F. Gelbard MK, et al. J Urol. 1993 Jan;149(1):56-8. doi: 10.1016/s0022-5347(17)35998-0. J Urol. 1993. PMID: 8417217 Clinical Trial.

10

Dystrophic penile calcification in Peyronie's disease.

Gelbard MK. Gelbard MK. J Urol. 1988 Apr;139(4):738-40. doi: 10.1016/s0022-5347(17)42617-6. J Urol. 1988. PMID: 3352034

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters